SCHEMBL3921148

SCHEMBL3921148

CC(C)(C)[Si](C)(C)Oc1ccc(N)c(OCc2ccccc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 1/20 0.43
MAOB P27338 2/20 0.42
MAPT P10636 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 1/20 0.42
MAOA P21397 1/20 0.42
RAB9A P51151 1/20 0.42
LTA4H P09960 1/20 0.41
MAPK14 Q16539 1/20 0.41
PIN1 Q13526 1/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
DCPS Q96C86 1/20 0.39
APP P05067 1/20 0.38
STAT3 P40763 1/20 0.38
HTT P42858 1/20 0.38
ALOX5 P09917 1/20 0.38
CYP3A4 P08684 1/20 0.38
BRD4 O60885 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5522119 0.80 LMNA (0.53) MAOBMAPTL3MBTL1SMN1; SMN2GAA
SCHEMBL4053551 0.80 MAOB (0.59) MAOBMAPTL3MBTL1SMN1; SMN2GAA
SCHEMBL20742253 0.80 TUBB1 (0.44) MAOBMAPTL3MBTL1SMN1; SMN2MAOA
SCHEMBL3918395 0.79 MEN1 (0.45) MAPTRAB9APIN1
SCHEMBL2380553 0.79 MAOB (0.59) MAOBMAOAALOX5
SCHEMBL3915606 0.79 MAOB (0.58) MAOBMAPTL3MBTL1SMN1; SMN2GAA
SCHEMBL30189780 0.79 MAOB (0.58) MAOBMAPTL3MBTL1SMN1; SMN2GAA
SCHEMBL22281219 0.78 MAOB (0.51) MAOBMAPTL3MBTL1SMN1; SMN2TDP1
SCHEMBL15472407 0.76 MAOB (0.47) MAOB
SCHEMBL647614 0.76 MAOB (0.50) MAOBMAPTL3MBTL1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084448-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 US disclosed
US-20090181928-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-07-16 US disclosed
EP-2038267-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE Novartis AG (CH) 2009-03-25 EP disclosed
WO-2007115058-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE NOVARTIS AG (CH) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181928-A1 ORGANIC COMPOUNDS PTPRS, PTPRO, PTPRC ALOX5AP 472/4885MAOB 1270/4885MAPT 3315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.